Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ed as unequivocal relief or the presence of one or two consecutive 15 minute assessments consistent with improvement immediately prior to discharge, occurred in 73 percent of attacks within one hour, and 95 percent within four hours;
  • 65 percent of laryngeal attacks achieved unequivocal relief or at least one report consistent with improvement immediately prior to discharge within one hour, and 90 percent within four hours;
  • Of the 84 laryngeal attacks, none required intubation after the receipt of Cinryze;
  • Responses to Cinryze in subjects with more than one attack did not diminish with subsequent repeated administration;
  • Infusion site pain, joint swelling, rash, and sinusitis were reported as treatment-emergent Cinryze-related adverse events.  

  • In a poster entitled, "Open-Label Use of Nanofiltered C1 Esterase Inhibitor (Human) (nf-C1 INH) for Treatment of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Timothy Craig, M.D. of the Hershey Medical Center in Harrisburg, PA, presented open label experience with Cinryze in treating 121 HAE attacks in 22 pediatric patients with HAE. Data from this study included the following:

    • The overall median time to beginning of relief of all attacks was 15 minutes;
    • Overall response rates within 4 hours were 89 to 97 percent for unequivocal relief and clinical relief, respectively;
    • No subjects with a laryngeal attack required intubation;
    • In subjects who were treated for multiple attacks, repeated therapy with Cinryze did not diminish the response to treatment;
    • Of the 121 acute attacks treated with Cinryze, 88 attacks were treated with one dose of Cinryze; 33 attacks required two doses;
    • There were no serious adverse events, and no adverse events were considered related to Cinryze.  No subject discontinued study drug due to an adverse event;  
    • There was no evid
      '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
    2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
    3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
    4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
    5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
    6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
    8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
    10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
    11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, Inc., ... in noninvasive medical monitoring, today announced that the Food ... 3231 OEM/eHealth finger pulse oximeter for use in ... oximeter plugs into a telemedicine hub or kiosk through ... rate in pediatric to adult patients. The Model 3231 ...
    (Date:8/28/2014)... R.I. , Aug. 28, 2014  In recognition ... developing health complications from the flu, pneumonia, shingles ... ® have declared September to be Senior ... they age, it is important that adults ages ... on their vaccinations. CVS pharmacists and MinuteClinic nurse ...
    (Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
    Breaking Medicine Technology:Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
    ... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
    ... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
    Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
    (Date:8/28/2014)... To kick off the fall season of sporting ... retailers across the country are offering 0% financing for ... Tub Tailgate Event is from August 29th-September 15th. ... and to apply early! , As the leader in ... of outdoor hot tubs with exclusive features at your ...
    (Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
    (Date:8/28/2014)... 2014 One in every 200 Ontarians has been ... of people living with the disease increasing by 64 ... study by researchers at the Institute for Clinical Evaluative ... and the Ottawa Hospital Research Institute. That puts Ontario ... world. , The study, published this week in ...
    (Date:8/28/2014)... 28, 2014 BCC Research ( http://www.bccresearch.com ... SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the global market ... in 2013. Driven by the need for replacement of ... in emerging geographies, the market is expected to grow ... (CAGR) of 8.5% from 2013 through 2018. , While ...
    (Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
    Breaking Medicine News(10 mins):Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3
    ... ORLEANS, Sept. 28 Sanarus Medical today announced ... centers across,the country. These Centers, including breast care ... with Sanarus to,increase the awareness and availability of ... breast tumors, known as,fibroadenomas. Sanarus will host a ...
    ... Sept. 28 Today, at the Clinton,Global Initiative, ... total value is $1,000,000. Fulvio,Renoldi Bracco, Bracco AMT,s ... company and said that the partnership would provide ... Heart Hospital, in,Changchun City, Jilin Province, China -- ...
    ... N.J., Sept. 28 Whether she is giving a,keynote ... Esther Paik Goodhart conveys optimism and possibility. "Only ... I have,",says Goodhart with a warm laugh, "I,m a ... I teach Hebrew at three temples,and I,m running for ...
    ... Inc. ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer ... be unable to file its Annual Report on,Form 10-K ... a timely basis because,it requires additional time to complete ... Annual Report on Form 10-K no later than,October 15, ...
    ... 28 Amid increasing pressure to combat,childhood obesity, the ... eleven-year-olds will lumber forward, breaking the $1,billion mark in ... the,U.S., a new report from market research publisher Packaged ... of kids, licensed food and,beverage products rose 9%, from ...
    ... University of Kentucky Center for Poverty Research has received ... Association of America Foundation (MOWAAF) to study the economic ... in America. , James Ziliak, Gatton Endowed Chair of ... at UK, part of the Gatton College of Business ...
    Cached Medicine News:Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2Health News:Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI 2Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 3Health News:Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids' Licensed Foods and Beverages 2Health News:Center for Poverty Research to study senior hunger in America 2
    ... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
    ... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
    ... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
    ... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
    Medicine Products: